{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:28:31Z","timestamp":1788290911558,"version":"build-2803163510"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01236-x","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:49:24Z","timestamp":1784558964000},"page":"521-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8195-4396","authenticated-orcid":false,"given":"Hendrik","family":"Sch\u00fcrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-403X","authenticated-orcid":false,"given":"Grainne M.","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sciortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9055-5338","authenticated-orcid":false,"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-5639","authenticated-orcid":false,"given":"Maximilian","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-8994","authenticated-orcid":false,"given":"Kenneth P.","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6725-9829","authenticated-orcid":false,"given":"Ina","family":"Pretzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. Lancet (Lond, Engl). 2025;405:1182\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2.","journal-title":"Lancet (Lond, Engl)"},{"key":"1236_CR2","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403\u201313. https:\/\/doi.org\/10.1200\/JCO.1997.15.6.2403.","journal-title":"J Clin Oncol"},{"key":"1236_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/nejmoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/nejmoa1011923.","journal-title":"N Engl J Med"},{"key":"1236_CR4","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/nejmoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406. https:\/\/doi.org\/10.1056\/nejmoa1809775.","journal-title":"N Engl J Med"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/nejmoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317. https:\/\/doi.org\/10.1056\/nejmoa1903387.","journal-title":"N Engl J Med"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007.","journal-title":"Eur J Cancer"},{"key":"1236_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:987\u20131002. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.009.","journal-title":"Ann Oncol"},{"key":"1236_CR8","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38:3217\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01364.","journal-title":"J Clin Oncol"},{"key":"1236_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMOA1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMOA1304369.","journal-title":"N Engl J Med"},{"key":"1236_CR10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(23)01366-1.","journal-title":"Lancet"},{"key":"1236_CR11","doi-asserted-by":"publisher","unstructured":"Carrato A, Pazo-Cid R, MacArulla T, et al. Nab-paclitaxel plus gemcitabine and FOLFOX in metastatic pancreatic cancer. NEJM Evid. 2024;3. https:\/\/doi.org\/10.1056\/EVIDOA2300144.","DOI":"10.1056\/EVIDOA2300144"},{"key":"1236_CR12","doi-asserted-by":"publisher","first-page":"S1149","DOI":"10.1016\/j.annonc.2025.08.2838","volume":"36","author":"CB Westphalen","year":"2025","unstructured":"Westphalen CB, Gaska T, Reichert M, et al. 2221P Final results of FOOTPATH: a randomized, open-label phase-II study of liposomal irinotecan\u00a0+\u00a05-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine\/nab-paclitaxel in treatment-na\u00efve metastatic pancreatic cancer. Ann Oncol. 2025;36:S1149\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2838.","journal-title":"Ann Oncol"},{"key":"1236_CR13","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1016\/S0140-6736(25)01685-X","volume":"406","author":"M Reni","year":"2025","unstructured":"Reni M, Macchini M, Orsi G, et al. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2\u00a0\u00d7\u00a02 factorial phase 3 trial. Lancet. 2025;406:2945\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(25)01685-X.","journal-title":"Lancet"},{"key":"1236_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","volume":"29","author":"S Ueda","year":"2004","unstructured":"Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004;29:e1\u20138. https:\/\/doi.org\/10.1097\/00006676-200407000-00061.","journal-title":"Pancreas"},{"key":"1236_CR15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960\u20136. https:\/\/doi.org\/10.1200\/JCO.2006.07.9525.","journal-title":"J Clin Oncol"},{"key":"1236_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104528","volume":"10","author":"T Conroy","year":"2025","unstructured":"Conroy T, Ducreux M. ESMO clinical practice guideline express update on the management of metastatic pancreatic cancer. ESMO Open. 2025;10:104528. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104528.","journal-title":"ESMO Open"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132\u20138. https:\/\/doi.org\/10.1038\/bjc.2014.418.","journal-title":"Br J Cancer"},{"key":"1236_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese AM, Perry MA, Chou JF, et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat Med. 2025;31:466. https:\/\/doi.org\/10.1038\/s41591-024-03362-3.","journal-title":"Nat Med"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael BJ, Hruban RH, Aguirre AJ, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.007.","journal-title":"Cancer Cell"},{"issue":"1","key":"1236_CR20","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1038\/s41467-025-60808-z","volume":"16","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, Jang GH, Grant RC, et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat Commun. 2025;16(1):5919. https:\/\/doi.org\/10.1038\/s41467-025-60808-z.","journal-title":"Nat Commun"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/nejm198809013190901","volume":"319","author":"B Vogelstein","year":"1988","unstructured":"Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic Alterations during Colorectal-Tumor Development. N Engl J Med. 1988;319:525\u201332. https:\/\/doi.org\/10.1056\/nejm198809013190901.","journal-title":"N Engl J Med"},{"key":"1236_CR22","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-12-0315","volume":"18","author":"CA Iacobuzio-Donahue","year":"2012","unstructured":"Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res. 2012;18:4257\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0315.","journal-title":"Clin Cancer Res"},{"key":"1236_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/NATURE19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538:378\u201382. https:\/\/doi.org\/10.1038\/NATURE19823.","journal-title":"Nature"},{"key":"1236_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell. 2024;42:1614\u201329.e5. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.002.","journal-title":"Cancer Cell"},{"key":"1236_CR25","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1158\/1538-7445.AM2025-3966","volume":"85","author":"A Wenger","year":"2025","unstructured":"Wenger A, Bacchi K, Sun H, et al. Abstract 3966: divergent immune responses in pancreatic cancer driven by KRAS mutations. Cancer Res. 2025;85:3966\u20133966. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3966.","journal-title":"Cancer Res"},{"key":"1236_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/2159-8290.CD-19-1006","volume":"10","author":"GA Hobbs","year":"2019","unstructured":"Hobbs GA, Baker NM, Miermont AM, et al. Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 2019;10:104. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1006.","journal-title":"Cancer Discov"},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-3-030-94004-1_11","volume":"98","author":"GA Hobbs","year":"2022","unstructured":"Hobbs GA, Der CJ. KRASG12R-independent macropinocytosis in pancreatic cancer. Subcell Biochem. 2022;98:205\u201321. https:\/\/doi.org\/10.1007\/978-3-030-94004-1_11.","journal-title":"Subcell Biochem"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","volume":"18","author":"T Pantsar","year":"2019","unstructured":"Pantsar T. The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J. 2019;18:189. https:\/\/doi.org\/10.1016\/j.csbj.2019.12.004.","journal-title":"Comput Struct Biotechnol J"},{"key":"1236_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111623","volume":"41","author":"G Ramakrishnan","year":"2022","unstructured":"Ramakrishnan G, Parajuli P, Singh P, et al. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Cell Rep. 2022;41:111623. https:\/\/doi.org\/10.1016\/j.celrep.2022.111623.","journal-title":"Cell Rep"},{"key":"1236_CR30","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res. 2015;13:1325\u201335. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0203.","journal-title":"Mol Cancer Res"},{"key":"1236_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1158\/2159-8290.CD-11-0347","volume":"2","author":"EA Collisson","year":"2012","unstructured":"Collisson EA, Trejo CL, Silva JM, et al. A central role for RAF\u2192MEK\u2192ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012;2:685\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0347.","journal-title":"Cancer Discov"},{"key":"1236_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.28","volume":"4","author":"SN Payne","year":"2015","unstructured":"Payne SN, Maher ME, Tran NH, et al. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. 2015;4:e169. https:\/\/doi.org\/10.1038\/oncsis.2015.28.","journal-title":"Oncogenesis"},{"key":"1236_CR33","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1073\/pnas.0308531101","volume":"101","author":"JP Brunet","year":"2004","unstructured":"Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA. 2004;101:4164\u20139. https:\/\/doi.org\/10.1073\/pnas.0308531101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1236_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/NM.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500\u20133. https:\/\/doi.org\/10.1038\/NM.2344.","journal-title":"Nat Med"},{"key":"1236_CR35","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/NG.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168\u201378. https:\/\/doi.org\/10.1038\/NG.3398.","journal-title":"Nat Genet"},{"key":"1236_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352. https:\/\/doi.org\/10.1038\/nature16965.","journal-title":"Nature"},{"key":"1236_CR37","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo F, Nicolle R, Blum Y, et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology. 2018;155:1999\u20132013.e3. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.033.","journal-title":"Gastroenterology"},{"issue":"2","key":"1236_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52(2):231\u201340. https:\/\/doi.org\/10.1038\/s41588-019-0566-9.","journal-title":"Nat Genet"},{"key":"1236_CR39","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO-25-00436","volume":"43","author":"JJ Knox","year":"2025","unstructured":"Knox JJ, O\u2019Kane G, King D, et al. PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J Clin Oncol. 2025;43:3355\u201368. https:\/\/doi.org\/10.1200\/JCO-25-00436.","journal-title":"J Clin Oncol"},{"key":"1236_CR40","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0177.","journal-title":"Cancer Discov"},{"key":"1236_CR41","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane GM, Grunwald BT, Jang GH, et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res. 2020;26:4901\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3724.","journal-title":"Clin Cancer Res"},{"key":"1236_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13747","author":"M Metzenmacher","year":"2024","unstructured":"Metzenmacher M, Zaun G, Trajkovic-Arsic M, et al. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Mol Oncol. 2024. https:\/\/doi.org\/10.1002\/1878-0261.13747.","journal-title":"Mol Oncol"},{"issue":"8066","key":"1236_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-025-08927-x","volume":"642","author":"G Pei","year":"2025","unstructured":"Pei G, Min J, Rajapakshe KI, et al. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Nature. 2025;642(8066):212\u201321. https:\/\/doi.org\/10.1038\/s41586-025-08927-x.","journal-title":"Nature"},{"key":"1236_CR44","doi-asserted-by":"publisher","unstructured":"Lucarelli D, Parikh S, Jim\u00e9nez S, et al. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer. 2026. bioRxiv 2026.03.19.712924. https:\/\/doi.org\/10.64898\/2026.03.19.712924.","DOI":"10.64898\/2026.03.19.712924"},{"key":"1236_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2020.12.029","volume":"146","author":"M Haas","year":"2021","unstructured":"Haas M, Waldschmidt DT, Stahl M, et al. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: the randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the burden of\u2026. Eur J Cancer. 2021;146:95\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.029.","journal-title":"Eur J Cancer"},{"key":"1236_CR46","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","volume":"28","author":"PA Philip","year":"2010","unstructured":"Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605\u201310. https:\/\/doi.org\/10.1200\/JCO.2009.25.7550.","journal-title":"J Clin Oncol"},{"key":"1236_CR47","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/annonc\/mds135","volume":"23","author":"A Gon\u00e7alves","year":"2012","unstructured":"Gon\u00e7alves A, Gilabert M, Fran\u00e7ois E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012;23:2799\u2013805. https:\/\/doi.org\/10.1093\/annonc\/mds135.","journal-title":"Ann Oncol"},{"key":"1236_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.dld.2013.09.020","volume":"46","author":"S Cascinu","year":"2014","unstructured":"Cascinu S, Berardi R, Sobrero A, et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized phase II study. Dig Liver Dis. 2014;46:182\u20136. https:\/\/doi.org\/10.1016\/j.dld.2013.09.020.","journal-title":"Dig Liver Dis"},{"key":"1236_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/cam4.208","volume":"3","author":"DB Cardin","year":"2014","unstructured":"Cardin DB, Goff L, Li CI, et al. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med. 2014;3:572\u20139. https:\/\/doi.org\/10.1002\/cam4.208.","journal-title":"Cancer Med"},{"key":"1236_CR50","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","volume":"50","author":"JR Infante","year":"2014","unstructured":"Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50:2072\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2014.04.024.","journal-title":"Eur J Cancer"},{"key":"1236_CR51","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/s41416-020-0776-z","volume":"122","author":"RMJM van Geel","year":"2020","unstructured":"van Geel RMJM, van Brummelen EMJ, Eskens FALM, et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1\/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. Br J Cancer. 2020;122:1166\u201374. https:\/\/doi.org\/10.1038\/s41416-020-0776-z.","journal-title":"Br J Cancer"},{"key":"1236_CR52","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/oncolo\/oyac237","volume":"28","author":"PM Grierson","year":"2023","unstructured":"Grierson PM, Tan B, Pedersen KS, et al. Phase Ib study of ulixertinib plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2023;28:e115\u201323. https:\/\/doi.org\/10.1093\/oncolo\/oyac237.","journal-title":"Oncologist"},{"key":"1236_CR53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2020","unstructured":"Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2020;70:148. https:\/\/doi.org\/10.1136\/gutjnl-2020-320726.","journal-title":"Gut"},{"key":"1236_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"key":"1236_CR55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/J.EJCA.2023.04.012","volume":"188","author":"J Ta\u00efeb","year":"2023","unstructured":"Ta\u00efeb J, Sayah L, Heinrich K, et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European cohort. Eur J Cancer. 2023;188:90\u20137. https:\/\/doi.org\/10.1016\/J.EJCA.2023.04.012.","journal-title":"Eur J Cancer"},{"key":"1236_CR56","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/JAMAONCOL.2024.3651\/","volume":"10","author":"CA O\u2019Connor","year":"2024","unstructured":"O\u2019Connor CA, Harrold E, Lin D, et al. Lynch syndrome and somatic mismatch repair variants in pancreas cancer. JAMA Oncol. 2024;10:1511\u20138. https:\/\/doi.org\/10.1001\/JAMAONCOL.2024.3651\/.","journal-title":"JAMA Oncol"},{"key":"1236_CR57","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.20.03238","volume":"39","author":"R Casolino","year":"2021","unstructured":"Casolino R, Paiella S, Azzolina D, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021;39:2617\u201331. https:\/\/doi.org\/10.1200\/JCO.20.03238.","journal-title":"J Clin Oncol"},{"key":"1236_CR58","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-21-2096\/673987\/AM\/PAN-CANCER-ANALYSIS-OF-HOMOLOGOUS-RECOMBINATION","volume":"28","author":"CB Westphalen","year":"2022","unstructured":"Westphalen CB, Fine AD, Andr\u00e9 F, et al. Pan-cancer Analysis of Homologous Recombination repair-associated gene alterations and genome-wide loss-of-heterozygosity score. Clin Cancer Res. 2022;28:1412\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2096\/673987\/AM\/PAN-CANCER-ANALYSIS-OF-HOMOLOGOUS-RECOMBINATION.","journal-title":"Clin Cancer Res"},{"key":"1236_CR59","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/J.GASTRO.2021.01.220","volume":"160","author":"T Golan","year":"2021","unstructured":"Golan T, O\u2019Kane GM, Denroche RE, et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. 2021;160:2119\u201332.e9. https:\/\/doi.org\/10.1053\/J.GASTRO.2021.01.220.","journal-title":"Gastroenterology"},{"key":"1236_CR60","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","volume":"24","author":"A Sehdev","year":"2018","unstructured":"Sehdev A, Gbolahan O, Hancock BA, et al. Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX. Clin Cancer Res. 2018;24:6204\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1472.","journal-title":"Clin Cancer Res"},{"key":"1236_CR61","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122:333\u20139. https:\/\/doi.org\/10.1038\/s41416-019-0582-7.","journal-title":"Br J Cancer"},{"key":"1236_CR62","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","volume":"38","author":"EM O\u2019Reilly","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020;38:1378\u201388. https:\/\/doi.org\/10.1200\/JCO.19.02931.","journal-title":"J Clin Oncol"},{"key":"1236_CR63","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0418.","journal-title":"Clin Cancer Res"},{"key":"1236_CR64","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497\u2013505. https:\/\/doi.org\/10.1200\/JCO.21.00003.","journal-title":"J Clin Oncol"},{"key":"1236_CR65","doi-asserted-by":"publisher","unstructured":"McVey JC, Wattenberg MM, Coho H, et al. Sequential platinum and PARP inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Sci Rep. 2026;16. https:\/\/doi.org\/10.1038\/S41598-026-35423-7.","DOI":"10.1038\/S41598-026-35423-7"},{"issue":"2","key":"1236_CR66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41590-025-02383-5","volume":"27","author":"W Traboulsi","year":"2026","unstructured":"Traboulsi W, Gaur P, Kundu S, et al. PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming. Nat Immunol. 2026;27(2):189\u201399. https:\/\/doi.org\/10.1038\/s41590-025-02383-5.","journal-title":"Nat Immunol"},{"key":"1236_CR67","doi-asserted-by":"publisher","unstructured":"Lei M, Gai J, McPhaul TJ, et al. Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer. Exp Hematol Oncol. 2025;14. https:\/\/doi.org\/10.1186\/s40164-025-00673-0.","DOI":"10.1186\/s40164-025-00673-0"},{"key":"1236_CR68","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.21037\/JGO-23-85\/COIF","volume":"14","author":"H Tan","year":"2023","unstructured":"Tan H, Hosein PJ. Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review. J Gastrointest Oncol. 2023;14:2249\u201359. https:\/\/doi.org\/10.21037\/JGO-23-85\/COIF.","journal-title":"J Gastrointest Oncol"},{"key":"1236_CR69","doi-asserted-by":"publisher","unstructured":"Park W, Umeda S, Hilmi M, et al. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer. 2026. bioRxiv 2026.03.15.711961. https:\/\/doi.org\/10.64898\/2026.03.15.711961.","DOI":"10.64898\/2026.03.15.711961"},{"issue":"7681","key":"1236_CR70","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran VP, \u0141uksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512\u20136. https:\/\/doi.org\/10.1038\/nature24462.","journal-title":"Nature"},{"key":"1236_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0611","author":"G Terrero","year":"2022","unstructured":"Terrero G, Datta J, Dennison J, et al. Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 2022. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0611.","journal-title":"JAMA Oncol"},{"key":"1236_CR72","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 2022;23:1009\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00369-2.","journal-title":"Lancet Oncol"},{"key":"1236_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-026-04299-5","volume":"2026","author":"W Park","year":"2026","unstructured":"Park W, O\u2019Connor CA, Chou JF, et al. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med. 2026;2026:1\u201311. https:\/\/doi.org\/10.1038\/s41591-026-04299-5.","journal-title":"Nat Med"},{"key":"1236_CR74","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/JCO.2026.44.16_SUPPL.4012","volume":"44","author":"V Chung","year":"2026","unstructured":"Chung V, Guthrie KA, Pishvaian MJ, et al. Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1\/2) mutations: SWOG S2001. J Clin Oncol. 2026;44:4012\u20134012. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_SUPPL.4012.","journal-title":"J Clin Oncol"},{"key":"1236_CR75","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/JNCCN.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19:439\u201357. https:\/\/doi.org\/10.6004\/JNCCN.2021.0017.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1236_CR76","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","volume":"28","author":"PA Philip","year":"2022","unstructured":"Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022;28:2704. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3581.","journal-title":"Clin Cancer Res"},{"key":"1236_CR77","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","volume":"10","author":"A Gkountakos","year":"2024","unstructured":"Gkountakos A, Singhi AD, Westphalen CB, et al. Fusion genes in pancreatic tumors. Trends Cancer. 2024;10:430\u201343. https:\/\/doi.org\/10.1016\/j.trecan.2024.01.009.","journal-title":"Trends Cancer"},{"key":"1236_CR78","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/nejmoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, Goto K, Kim D-W, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025;392:566. https:\/\/doi.org\/10.1056\/nejmoa2405008.","journal-title":"N Engl J Med"},{"key":"1236_CR79","unstructured":"FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma | FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic. Accessed 10 May 2026."},{"key":"1236_CR80","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24:925\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9.","journal-title":"Lancet Oncol"},{"key":"1236_CR81","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/S41698-024-00683-X","volume":"8","author":"L Stein","year":"2024","unstructured":"Stein L, Murugesan K, Reeser JW, et al. FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer. NPJ Precis Oncol. 2024;8:207. https:\/\/doi.org\/10.1038\/S41698-024-00683-X.","journal-title":"NPJ Precis Oncol"},{"key":"1236_CR82","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/IJMS25042366","volume":"25","author":"NWY Theik","year":"2024","unstructured":"Theik NWY, Muminovic M, Alvarez-Pinzon AM, et al. NTRK therapy among different types of cancers, review and future perspectives. Int J Mol Sci. 2024;25:2366. https:\/\/doi.org\/10.3390\/IJMS25042366.","journal-title":"Int J Mol Sci"},{"key":"1236_CR83","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","volume":"29","author":"ES Duke","year":"2023","unstructured":"Duke ES, Bradford D, Marcovitz M, et al. FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res. 2023;29:3573. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0459.","journal-title":"Clin Cancer Res"},{"key":"1236_CR84","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_404770","author":"MA Gouda","year":"2023","unstructured":"Gouda MA, Subbiah V. Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E\u2013positive adult and pediatric solid tumors. Am Soc Clin Oncol Educ B. 2023. https:\/\/doi.org\/10.1200\/EDBK_404770.","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"1236_CR85","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/PO.20.00494","volume":"5","author":"A Hendifar","year":"2021","unstructured":"Hendifar A, Blais EM, Wolpin B, et al. Retrospective Case Series Analysis of RAF Family Alterations inPancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021;5:1325\u201338. https:\/\/doi.org\/10.1200\/PO.20.00494.","journal-title":"JCO Precis Oncol."},{"key":"1236_CR86","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/S00280-023-04544-5","volume":"92","author":"DW Rasco","year":"2023","unstructured":"Rasco DW, Medina T, Corrie P, et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2023;92:15. https:\/\/doi.org\/10.1007\/S00280-023-04544-5.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1236_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00114","author":"V Gambardella","year":"2026","unstructured":"Gambardella V, McKean M, Kim R, et al. Phase I clinical trial evaluating safety, tolerability, and early activity of Exarafenib (KIN-2787), a highly selective Pan-RAF inhibitor, in BRAF-altered solid tumors or NRAS-mutant melanoma. JCO Oncol Adv. 2026. https:\/\/doi.org\/10.1200\/OA-25-00114.","journal-title":"JCO Oncol Adv"},{"key":"1236_CR88","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Li J, Bai Y, et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2023;41:5163. https:\/\/doi.org\/10.1200\/JCO.22.02630.","journal-title":"J Clin Oncol"},{"key":"1236_CR89","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351. https:\/\/doi.org\/10.1038\/nature12796.","journal-title":"Nature"},{"key":"1236_CR90","doi-asserted-by":"publisher","unstructured":"Salem ME, El-Refai SM, Sha W, et al. Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers. JCO Precis Oncol. 2022;6. https:\/\/doi.org\/10.1200\/po.21.00245.","DOI":"10.1200\/po.21.00245"},{"key":"1236_CR91","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 2023;41:4097\u2013106. https:\/\/doi.org\/10.1200\/JCO.23.00434.","journal-title":"J Clin Oncol"},{"key":"1236_CR92","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/nejmoa2208470","volume":"388","author":"JH Strickler","year":"2022","unstructured":"Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C\u2013mutated advanced pancreatic cancer. N Engl J Med. 2022;388:33. https:\/\/doi.org\/10.1056\/nejmoa2208470.","journal-title":"N Engl J Med"},{"key":"1236_CR93","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65:3123\u201333. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01688.","journal-title":"J Med Chem"},{"key":"1236_CR94","unstructured":"Study Details | NCT05737706 | Study of MRTX1133 in patients with advanced solid tumors harboring a KRAS G12D mutation | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05737706. Accessed 10 May 2026."},{"key":"1236_CR95","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0027.","journal-title":"Cancer Discov"},{"key":"1236_CR96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2605555;WGROUP:STRING:MMS","author":"EM O\u2019Reilly","year":"2026","unstructured":"O\u2019Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMOA2605555;WGROUP:STRING:MMS.","journal-title":"N Engl J Med"},{"key":"1236_CR97","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","volume":"44","author":"JM Riedl","year":"2026","unstructured":"Riedl JM, Matsubara H, McNeil R, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026;44:471\u201397. https:\/\/doi.org\/10.1016\/j.ccell.2026.01.001.","journal-title":"Cancer Cell"},{"key":"1236_CR98","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1538-7445.am2025-390","volume":"85","author":"ED Lew","year":"2025","unstructured":"Lew ED, Brooun A, Lam J, et al. Abstract 390: ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumors. Cancer Res. 2025;85:390\u2013390. https:\/\/doi.org\/10.1158\/1538-7445.am2025-390.","journal-title":"Cancer Res"},{"key":"1236_CR99","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMOA2505783;JOURNAL:JOURNAL:NEJMS","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N Engl J Med. 2026;394:1790\u2013802. https:\/\/doi.org\/10.1056\/NEJMOA2505783;JOURNAL:JOURNAL:NEJMS.","journal-title":"N Engl J Med"},{"key":"1236_CR100","doi-asserted-by":"publisher","first-page":"S1626","DOI":"10.1016\/j.annonc.2025.09.099","volume":"36","author":"A Zhou","year":"2025","unstructured":"Zhou A, Li Z, Sun Y, et al. LBA84 efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC). Ann Oncol. 2025;36:S1626. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.099.","journal-title":"Ann Oncol"},{"key":"1236_CR101","doi-asserted-by":"publisher","first-page":"S1146","DOI":"10.1016\/j.annonc.2025.08.2832","volume":"36","author":"L Wang","year":"2025","unstructured":"Wang L, Jiang K, Li W, et al. 2215O HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: a phase Ib\/II study. Ann Oncol. 2025;36:S1146. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2832.","journal-title":"Ann Oncol"},{"key":"1236_CR102","doi-asserted-by":"publisher","first-page":"LB430","DOI":"10.1158\/1538-7445.am2025-lb430","volume":"85","author":"YJ Zhang","year":"2025","unstructured":"Zhang YJ, Silva JM, Zhang YW, et al. Abstract LB430: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity. Cancer Res. 2025;85:LB430\u2013LB430. https:\/\/doi.org\/10.1158\/1538-7445.am2025-lb430.","journal-title":"Cancer Res"},{"key":"1236_CR103","doi-asserted-by":"publisher","first-page":"C019","DOI":"10.1158\/2326-6074.IO2026-C019","volume":"14","author":"MM Ayala","year":"2026","unstructured":"Ayala MM, Perez PS, Quinones A, et al. Abstract C019: RMC-5127, a RAS(ON) G12V-selective inhibitor, drives durable tumor regressions and increases T cell infiltration in KRAS G12V-driven syngeneic models. Cancer Immunol Res. 2026;14:C019. https:\/\/doi.org\/10.1158\/2326-6074.IO2026-C019.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"1236_CR104","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","volume":"25","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE. Targeted protein degradation for cancer therapy. Nat Rev Cancer. 2025;25(7):493\u2013516. https:\/\/doi.org\/10.1038\/s41568-025-00817-8.","journal-title":"Nat Rev Cancer"},{"key":"1236_CR105","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMOA2600752","volume":"394","author":"W Park","year":"2026","unstructured":"Park W, Kasi A, Spira AI, et al. Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026;394:1409\u201320. https:\/\/doi.org\/10.1056\/NEJMOA2600752.","journal-title":"N Engl J Med"},{"key":"1236_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011441","volume":"13","author":"C Roy","year":"2025","unstructured":"Roy C, Sewastianik T, Saenz I, et al. Regional distribution of HLA frequencies in the USA: implications for TCR-based therapies. J Immunother Cancer. 2025;13:e011441. https:\/\/doi.org\/10.1136\/jitc-2024-011441.","journal-title":"J Immunother Cancer"},{"key":"1236_CR107","doi-asserted-by":"publisher","first-page":"e14533","DOI":"10.1200\/JCO.2024.42.16_SUPPL.E14533","volume":"42","author":"J Ma","year":"2024","unstructured":"Ma J, Tubb V, Mojadidi M, et al. Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition. J Clin Oncol. 2024;42:e14533. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.E14533.","journal-title":"J Clin Oncol"},{"key":"1236_CR108","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg ZA, Weekes CD, Furqan M, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025;31:3648. https:\/\/doi.org\/10.1038\/s41591-025-03876-4.","journal-title":"Nat Med"},{"key":"1236_CR109","doi-asserted-by":"publisher","first-page":"A1555","DOI":"10.1136\/jitc-2025-sitc2025.1317","volume":"13","author":"LK McNeil","year":"2025","unstructured":"McNeil LK, Perry JR, Snyder JP, et al. 1317 AMPLIFY-7P phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma. J Immunother Cancer. 2025;13:A1555\u2013A1555. https:\/\/doi.org\/10.1136\/jitc-2025-sitc2025.1317.","journal-title":"J Immunother Cancer"},{"key":"1236_CR110","doi-asserted-by":"publisher","unstructured":"Huff AL, Haldar SD, Gergis AA, et al. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat Commun. 2026;17(1):1538\u2013. https:\/\/doi.org\/10.1038\/s41467-026-68324-4.","DOI":"10.1038\/s41467-026-68324-4"},{"key":"1236_CR111","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"1236_CR112","doi-asserted-by":"publisher","first-page":"A081","DOI":"10.1158\/1535-7163.targ-25-a081","volume":"24","author":"I Aronchik","year":"2025","unstructured":"Aronchik I, Kar S, Zhuang Y, et al. Abstract A081: resistance mechanisms to monotherapy RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC inform therapeutic combination strategies. Mol Cancer Ther. 2025;24:A081\u2013A081. https:\/\/doi.org\/10.1158\/1535-7163.targ-25-a081.","journal-title":"Mol Cancer Ther"},{"key":"1236_CR113","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","volume":"36","author":"JM Riedl","year":"2025","unstructured":"Riedl JM, Fece de la Cruz F, Lin JJ, et al. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. Ann Oncol. 2025;36:682\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.020.","journal-title":"Ann Oncol"},{"key":"1236_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67109-5","author":"T Ivanisevic","year":"2025","unstructured":"Ivanisevic T, Ma Y, Van Boxel E, et al. Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-67109-5.","journal-title":"Nat Commun"},{"key":"1236_CR115","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","volume":"14","author":"A Singhal","year":"2024","unstructured":"Singhal A, Styers HC, Rub J, et al. A classical epithelial state drives acute resistance to KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2122\u201334. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0740.","journal-title":"Cancer Discov"},{"key":"1236_CR116","doi-asserted-by":"publisher","unstructured":"Werba G, Weissinger D, Kawaler EA, et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat Commun. 2023;14(1):797\u2013. https:\/\/doi.org\/10.1038\/s41467-023-36296-4.","DOI":"10.1038\/s41467-023-36296-4"},{"key":"1236_CR117","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/J.CELL.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic KRAS maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656. https:\/\/doi.org\/10.1016\/J.CELL.2012.01.058.","journal-title":"Cell"},{"key":"1236_CR118","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/J.CCR.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15:489. https:\/\/doi.org\/10.1016\/J.CCR.2009.03.022.","journal-title":"Cancer Cell"},{"key":"1236_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39:110993. https:\/\/doi.org\/10.1016\/j.celrep.2022.110993.","journal-title":"Cell Rep"},{"key":"1236_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2026.03.031","volume":"0","author":"B Sang","year":"2026","unstructured":"Sang B, Ye LF, Fu Z, et al. Disrupted molecular glue complex drives RAS inhibitor resistance. Cell. 2026;0:1\u201316. https:\/\/doi.org\/10.1016\/j.cell.2026.03.031.","journal-title":"Cell"},{"key":"1236_CR121","doi-asserted-by":"publisher","first-page":"56","DOI":"10.21037\/tgh-24-73","volume":"9","author":"K Saleh","year":"2024","unstructured":"Saleh K, Ibrahim R, Khoury R, et al. KRAS and EGFR inhibitors: a new step in the management of colorectal cancer. Transl Gastroenterol Hepatol. 2024;9:56. https:\/\/doi.org\/10.21037\/tgh-24-73.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1236_CR122","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973\u20137. https:\/\/doi.org\/10.1038\/nature09626.","journal-title":"Nature"},{"key":"1236_CR123","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20201414","volume":"218","author":"C Fedele","year":"2021","unstructured":"Fedele C, Li S, Teng KW, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021;218:e20201414. https:\/\/doi.org\/10.1084\/JEM.20201414.","journal-title":"J Exp Med"},{"key":"1236_CR124","doi-asserted-by":"publisher","unstructured":"Baltan\u00e1s FC, Kramer-Drauberg M, Garc\u00eda-Navas R, et al. SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD. Proc Natl Acad Sci USA. 2025;122. https:\/\/doi.org\/10.1073\/pnas.2422943122.","DOI":"10.1073\/pnas.2422943122"},{"key":"1236_CR125","doi-asserted-by":"publisher","unstructured":"Hafner P, Keller SJ, Chen X, et al. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Signal Transduct Target Ther. 2026;11(1):33\u2013. https:\/\/doi.org\/10.1038\/s41392-025-02563-7.","DOI":"10.1038\/s41392-025-02563-7"},{"key":"1236_CR126","doi-asserted-by":"publisher","unstructured":"Abuelafia AM, Santofimia-Casta\u00f1o P, Estaras M, et al. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Transl Oncol. 2025;57. https:\/\/doi.org\/10.1016\/j.tranon.2025.102421.","DOI":"10.1016\/j.tranon.2025.102421"},{"key":"1236_CR127","doi-asserted-by":"publisher","first-page":"12649","DOI":"10.1073\/pnas.1307218110","volume":"110","author":"X Jiang","year":"2013","unstructured":"Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2013;110:12649\u201354. https:\/\/doi.org\/10.1073\/pnas.1307218110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1236_CR128","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/2159-8290.CD-21-0190","volume":"11","author":"MJ Parsons","year":"2021","unstructured":"Parsons MJ, Tammela T, Dow LE. WNT as a driver and dependency in cancer. Cancer Discov. 2021;11:2413. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0190.","journal-title":"Cancer Discov"},{"key":"1236_CR129","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1073\/pnas.1508113112","volume":"112","author":"BK Koo","year":"2015","unstructured":"Koo BK, Van Es JH, Van Den Born M, Clevers H. Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia. Proc Natl Acad Sci USA. 2015;112:7548\u201350. https:\/\/doi.org\/10.1073\/pnas.1508113112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1236_CR130","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2022","unstructured":"Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRASG12C\u2013EGFR inhibition in colorectal cancer. Cancer Discov. 2022;13:41. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0405.","journal-title":"Cancer Discov"},{"key":"1236_CR131","doi-asserted-by":"publisher","unstructured":"Tian L, Li H, Cui H, et al. Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming. Cell Death Dis. 2025;16(1):785\u2013. https:\/\/doi.org\/10.1038\/s41419-025-08101-1.","DOI":"10.1038\/s41419-025-08101-1"},{"key":"1236_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100042","volume":"4","author":"EB Faber","year":"2024","unstructured":"Faber EB, Baca Y, Xiu J, et al. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status. ESMO Open Gastrointest Oncol. 2024;4:100042. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100042.","journal-title":"ESMO Open Gastrointest Oncol"},{"key":"1236_CR133","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","volume":"58","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, LeBleu VS, Ramirez EV, et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev Cell. 2023;58:1562\u201377.e8. https:\/\/doi.org\/10.1016\/j.devcel.2023.07.025.","journal-title":"Dev Cell"},{"key":"1236_CR134","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Han J, Hsu WH, et al. Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model. Cancer Discov. 2025;15:162. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0489.","journal-title":"Cancer Discov"},{"key":"1236_CR135","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the arginine methyltransferase PRMT5 in human cancer cells. Science. 2016;351:1214. https:\/\/doi.org\/10.1126\/science.aad5214.","journal-title":"Science"},{"key":"1236_CR136","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, Prenen H, Sacher A, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024;35:1138\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2339.","journal-title":"Ann Oncol"},{"key":"1236_CR137","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/jco.2025.43.16_suppl.3011","volume":"43","author":"KC Arbour","year":"2025","unstructured":"Arbour KC, George B, Henry JT, et al. BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007. J Clin Oncol. 2025;43:3011\u20133011. https:\/\/doi.org\/10.1200\/jco.2025.43.16_suppl.3011.","journal-title":"J Clin Oncol"},{"key":"1236_CR138","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","volume":"85","author":"K Drizyte-Miller","year":"2025","unstructured":"Drizyte-Miller K, Engstrom LD, Klomp JA, et al. Combination of the MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors is an effective treatment strategy for mtap-deleted KRAS-mutant pancreatic cancer. Cancer Res. 2025;85:3540\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-1507.","journal-title":"Cancer Res"},{"key":"1236_CR139","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2023;42:47. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"key":"1236_CR140","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005.","journal-title":"Ann Oncol"},{"key":"1236_CR141","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/jco.2025.43.16_suppl.4018","volume":"43","author":"RW Lentz","year":"2025","unstructured":"Lentz RW, Ng MCH, Yong W-P, et al. Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. J Clin Oncol. 2025;43:4018\u20134018. https:\/\/doi.org\/10.1200\/jco.2025.43.16_suppl.4018.","journal-title":"J Clin Oncol"},{"key":"1236_CR142","doi-asserted-by":"publisher","first-page":"S1145","DOI":"10.1016\/j.annonc.2025.08.2831","volume":"36","author":"JJ Harding","year":"2025","unstructured":"Harding JJ, Strickler JH, Henry J, et al. 2214MO phase I basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein-targeting antibody-drug conjugate: results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC). Ann Oncol. 2025;36:S1145. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2831.","journal-title":"Ann Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01236-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:22Z","timestamp":1785503722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01236-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":142,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01236-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HS has received conference travel support from Servier. WP has received institutional research funding from Merck, Astellas, Revolution Medicines, Lepu Biopharma, Amgen, Verastem Oncology; has served in consulting or advisory roles for Astellas, Revolution Medicines, Innovent Biologics, Regeneron, KeyQuest, IMGT, Expert Connect, TD Cowen, Guidepoint; has received honoraria for CME from American Physician Institute, Curio, Integrity, EPICS, SignifyMD, PER; has received travel support from Amgen, DAVA Oncology; holds licensing interests in Saccharo Inc.; and is an inventor on a provisional US patent related to microhomology mediated end joining deletion footprint (MDF) biomarkers of POLQ associated DNA repair (U.S. Provisional Patent No. 63\/887,326). GMO\u2019K. has acted as a consultant and\/or adviser of AstraZeneca, Roche, Servier, Regeneron, and Zymeworks; has acted as a speaker on behalf of Merck Sharp & Dohme; has received research grants from AstraZeneca and Roche; and has received travel support from Merck Sharp & Dohme, Novartis, Roche, and Takeda. CS declares no conflicts of interest. MN has received travel\/meeting expenses from AstraZeneca; has received speaker honoraria from Accademia della Medicina, Incyte, Servier, and Taiho; has received honoraria from Sandoz, Medpoint SRL, Incyte, AstraZeneca, and Servier for editorial collaboration; and has received consultant honoraria from Basilea Pharmaceutica, Incyte, MSD Italia, Servier, Astrazeneca, and Taiho. MR has received payments or honoraria for lectures, presentations, and participation in speakers\u2019 bureaus from Celgene, Falk, Servier, and Roche; and is academic consultant of BioMedX GmbH. KPO was named as an inventor on a patent application filed by Columbia University pertaining to the treatment of RAS inhibitor resistant tumors; and has received research funding from Revolution Medicines. IP has received honoraria for advisory boards from BeOne, Daiichi-Sankyo, and Taiho Oncology Europe GmbH and for lectures from Deutsche Bundesbank, NeoConnect, and Daiichi-Sankyo. CBW has served as an advisor for AstraZeneca, Daiichi Sankyo, BMS, Frankfurt Institute of Clinical Cancer Research (IKF), Incyte, Johnson & Johnson, Roche, Taiho; has received honoraria from Amgen, Astra Zeneca, Bayer, BMS, Daiichi Sankyo, Falk, GSK, Johnson & Johnson, Lilly, MSD, Merck, Pierre Fabre, QuIP GmbH, Roche, Servier; has received travel support from Astra Zeneca, Daiichi Sankyo, Bayer, Johnson & Johnson, Roche, Servier, Taiho; has received institutional research funding from Roche and ESMO; serves as an officer for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH), and Arbeitsgemeinschaft internistische Onkologie (AIO); is a member of the EU Commission expert group Mission Board for cancer; and is a member of the BMFTR steering committee Strategiekreis Dekade gegen Krebs.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HS: conceptualization, writing\u2014original draft, writing\u2014review and editing, visualization. WP\n                      :\n                      writing\u2014review and editing, GMO\u2019K: writing\u2014review and editing, CS: writing\u2014review and editing, visualization, MN: writing\u2014review and editing, MR: writing\u2014review and editing, KPO: writing\u2014review and editing, IP: writing\u2014original draft, writing\u2014review and editing, CBW: conceptualization, supervision, writing\u2014original draft, writing\u2014review and editing. All authors read and approved the final manuscript.","order":6,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}